Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
4 evidence topics · 3 sources
Investigational darovasertib tablet and crizotinib capsule in the OptimUM-02 trial
| Product | Pharmaceutical form | Route | Maximum daily dose (mg) |
|---|---|---|---|
| Darovasertib | “IDE196 (LXS196)”; “TABLET” | “ORAL” | “600” |
| Crizotinib | “Crizotinib 200mg hard capsules”; “CAPSULE, HARD” | “ORAL” | “400” |
Earlier darovasertib powder-in-capsule formulation in the OptimUM-01 trial
Darovasertib tablet strengths and commercial formulation
No evidence found.